UpToDate, Wolters Kluwer Health, and for editorial work from Elsevier. P.M.: CME‐related honoraria, or consulting fees from Angelini, AstraZeneca, Bial Foundation, Biogen, DGS‐Portugal, Janssen‐Cilag, Springer Healthcare and 2CA‐Braga. E.N.: Medical/Scientific Advisory Boards: Teva Pharmaceuticals, Myriad Genetics. C.P.: Research support from Biohaven Pharmaceuticals for mutisite industry‐sponsored clinical trial; royalties from Oxford University Press; consultant to Blackthorn Therapeutics, Teva Pharmaceuticals, Brainsway. N.S.: Research Support from Lundbeck LLC. SFT: Research support from Otsuka and Boehringer Ingelheim. P.M.T.: PT received a grant from Biogen, Inc., for work unrelated to this study. D.J.S.: Research grants or consultancy honoraria from Lundbeck and Sun.
